SHMN is the next big deal, triple digits gains to an 8 billion market in India
SHMN closed @ 0.063 up 21.15% on Friday, hitting a high of 0.077. SHMN is up 986.20% from its 52 week-low of 0.0058 from March of this year.
PSC thinks SHMN is a great opportunity for members to cash in.
SHMN closed on over 1.3 million in volume on Friday beating out its 10 average of 63,967 shares. The spike in volume has put SHMN on the radar. More eyes on SHMN will bring more money to the table.
SHMN is a great find at these levels. On a short term scale we are looking for SHMN to run for a break past .10.
PSC thinks SHMN is going to run up harder putting more money in members’ pockets.
SHMN is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. SHMN is headquartered in North America with manufacturing sites in India.
SHMN is a fully reporting company on the pink sheets. Transparency is key and we think this may be a good indication that SHMN has bigger plans up its sleeve.
Investors are flocking to SHMN and tapping into a billion dollar market for just pennies. India has the second fastest growing economy to China and investors are fast to notice.
India is the second largest growing economy after China, but it will overtake its neighbouring country by 2018.
SHMN is on the verge of huge potential and we want members to cash in on this opportunity.
Bloomberg BusinessWeek reports that a branded generic-medicine unit in India, Piramal Healthcare Ltd., was bought by an Illinois based company, The Abbott Park, for $3.72 billion.
This acquisition marks the second-largest takeover in India’s health-care industry, giving Abbott a 7% stake in the $8 billion Indian pharmaceutical market.
SHMN is looking like a great investment as analysts report that this is not the last deal investors can expect from India.
SHMN is going to be a growth driver in your portfolio.
U.S. based pharma companies are turning to developing countries to increase their revenue potential. This marks tremendous growth opportunity for SHMN for 2010 and beyond.
2008 marked the biggest takeover in South Asian nation’s pharmaceutical industry when 64% of India’s largest drug maker, Ranbaxy Laboratories, was bought by a Tokyo-based company for $5.45 billion. Pfizer Inc. has also been licensing products from Indian generic-drug maker Aurobindo Pharma Ltd.
It’s also reported that the recent Piramal sell-off is likely to produce a domino effect in the medicine market in India, with more companies looking at selling their businesses to international buyers.
http://www.dnaindia.com/india/report_rise-of-big-pharma-will-make-drugs-dearer_1386487
Members should re-read the PR’s from SHMN and assess the upside potential. There is money to be made here. SHMN operates in a market that is set to explode.
Industry estimates suggest, that by 2015, when the Indian pharmaceutical market would be worth $20 billion.
SHMN recently reported that it has expanded its sales to Africa. This is an additional path of revenue flow from the company and SHMN’s entry in the African market is going to have positive effects in members’ portfolios.
SOHM India Signs Sales and Marketing Agreement to Sell Branded Generic Pharmaceutical Products in Africa
http://www.stockwatch.com/newsit/newsit_newsit.aspx?bid=U-i0623616-U%3aSHMN-20100521&symbol=SHMN®ion=U
SOHM’s Branded Generic Pharmaceutical Line Expands to 280 Products
the article is originated by pennystockchaser.com
